<DOC>
	<DOCNO>NCT02797236</DOCNO>
	<brief_summary>This first-in-human , single-center , single-blinded , observer-masked randomize , dose escalation ( two dos ) , placebo-controlled study healthy volunteer .</brief_summary>
	<brief_title>SF2a-TT15 Conjugate Vaccine Healthy Adult Volunteers</brief_title>
	<detailed_description>Subjects assign one two cohort . 1 . Cohort 1 receive low dose 2 μg vaccine ( without alum adjuvant ) match placebo . 2 . Cohort 2 receive high dose 10 μg vaccine ( without alum adjuvant ) match placebo . Eligible subject randomize receive 2 μg dose 10 µg without alum match placebo , ratio 3:1 , three single IM injection . There interval 28 ( ±3 ) day ) treatment . The study conduct stepwise approach `` Pioneer '' Group 2 subject ( one receive active vaccine one receiving match placebo ) receive first injection . These subject remain in-house 24-hours medical observation first injection ( require subsequent injection ) Once establish safety concern non-adjuvanted `` Pioneer '' Groups ( less 48 hr ) , next `` Pioneer '' group ( one subject receiving adjuvanted 2 μg vaccine one receiving match alum placebo ) inject . If safety concern raise group also , less 48 hr , rest subject may receive first injection .</detailed_description>
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion Subjects general good health opinion investigator determine medical history , vital sign physical examination . Negative human leukocyte antigen ( HLA ) B27 history reactive arthritis Negative HIV , Hepatitis B Hepatitis C serology test . Blood level Shigella flexneri 2a LPS IgG antibodies ≤ percentile 80 No known history alcohol abuse Exclusion criterion Subjects history clinically significant gastrointestinal disorder history frequent diarrhea , nausea emesis , regardless etiology . Individuals immunosuppressive disease immunosuppressive therapy History cultureproven S. flexneri . Individuals household contact with/and /or intimate exposure individual laboratory confirm S. flexneri . Having travel countries/areas highly endemic S. flexneri within 3 month prior enrolment . Previous participation study Shigellavaccine candidate administer . Known contraindication , hypersensitivity and/or allergy investigational product excipients . Known hypersensitivity and/or allergy drug vaccine Women pregnant breastfeeding , childbearing age use plan use acceptable birth control measure , duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>conjugate vaccine</keyword>
	<keyword>Shigella flexneri 2a</keyword>
	<keyword>safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Healthy adult</keyword>
</DOC>